-
公开(公告)号:US20100144649A1
公开(公告)日:2010-06-10
申请号:US12708932
申请日:2010-02-19
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K38/06 , A61K38/05 , C07K5/08 , C07D413/12 , C07D417/12 , C07D303/38 , A61P31/00 , A61P35/00 , A61P29/00 , A61P25/00
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
摘要翻译: 本发明的一个方面涉及优先抑制免疫蛋白酶体活性超过组成型蛋白酶体活性的抑制剂。 在某些实施方案中,本发明涉及治疗免疫相关疾病,包括施用本发明的化合物。 在某些实施方案中,本发明涉及治疗癌症,包括施用本发明的化合物。
-
公开(公告)号:US08080545B2
公开(公告)日:2011-12-20
申请号:US12708753
申请日:2010-02-19
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K31/5377
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
摘要翻译: 本发明的一个方面涉及优先抑制免疫蛋白酶体活性超过组成型蛋白酶体活性的抑制剂。 在某些实施方案中,本发明涉及治疗免疫相关疾病,包括施用本发明的化合物。 在某些实施方案中,本发明涉及治疗癌症,包括施用本发明的化合物。
-
公开(公告)号:US20120088762A1
公开(公告)日:2012-04-12
申请号:US13328909
申请日:2011-12-16
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K31/5377 , A61K31/404 , C07D303/38 , A61K31/336 , C07D413/12 , C07D417/12 , A61K31/427 , A61P37/06 , A61P1/00 , A61P3/10 , A61P25/00 , A61P17/06 , A61P19/02 , A61P37/08 , A61P11/06 , A61P17/00 , A61P37/00 , A61P31/18 , A61P35/00 , A61P35/02 , A61P29/00 , A61P11/08 , A61P1/18 , A61P9/10 , A61P31/04 , A61P31/12 , A61P33/00 , A61P25/28 , A61P25/16 , C07D405/12
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
摘要翻译: 本发明的一个方面涉及优先抑制免疫蛋白酶体活性超过组成型蛋白酶体活性的抑制剂。 在某些实施方案中,本发明涉及治疗免疫相关疾病,包括施用本发明的化合物。 在某些实施方案中,本发明涉及治疗癌症,包括施用本发明的化合物。
-
公开(公告)号:US08357683B2
公开(公告)日:2013-01-22
申请号:US13328909
申请日:2011-12-16
申请人: Kevin D. Shenk , Francesco Parlati , Han-jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K31/5377 , A61K31/427 , A61K31/404 , A61K31/336 , C07D413/12 , C07D417/12 , C07D405/12 , C07D303/38
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
-
公开(公告)号:US08080576B2
公开(公告)日:2011-12-20
申请号:US12708932
申请日:2010-02-19
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K31/404 , A61K31/381 , A61K31/336 , C07D209/04 , C07D333/52 , C07D303/02
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
-
公开(公告)号:US20100144648A1
公开(公告)日:2010-06-10
申请号:US12708753
申请日:2010-02-19
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
-
公开(公告)号:US07691852B2
公开(公告)日:2010-04-06
申请号:US11820490
申请日:2007-06-19
申请人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
发明人: Kevin D. Shenk , Francesco Parlati , Han-Jie Zhou , Catherine Sylvain , Mark S. Smyth , Mark K. Bennett , Guy J. Laidig
IPC分类号: A61K31/5377 , C07D413/02
CPC分类号: C07K5/1016 , A61K38/00 , C07D303/32 , C07D405/12 , C07D409/12 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06043 , C07K5/06052 , C07K5/0606 , C07K5/06078 , C07K5/06086 , C07K5/06113 , C07K5/08 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0819 , C07K5/0821 , C07K5/1008 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
摘要翻译: 本发明的一个方面涉及优先抑制免疫蛋白酶体活性超过组成型蛋白酶体活性的抑制剂。 在某些实施方案中,本发明涉及治疗免疫相关疾病,包括施用本发明的化合物。 在某些实施方案中,本发明涉及治疗癌症,包括施用本发明的化合物。
-
公开(公告)号:US09359398B2
公开(公告)日:2016-06-07
申请号:US13580112
申请日:2011-03-01
IPC分类号: A01N37/18 , A61K38/00 , A61P31/00 , A61P29/00 , A61P3/04 , A61P25/00 , A61P35/00 , A61K38/06 , A61K38/07 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C07K5/08 , C07D209/20 , C07D241/24 , C07D295/104 , C07D303/36 , C07D405/12
CPC分类号: C07K5/0827 , C07D209/20 , C07D241/24 , C07D295/104 , C07D303/36 , C07D405/12
摘要: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
摘要翻译: 本发明的一个方面涉及优先抑制免疫蛋白酶体活性超过组成型蛋白酶体活性的抑制剂。 在某些实施方案中,本发明涉及治疗免疫相关疾病,包括施用本发明的化合物。 在某些实施方案中,本发明涉及治疗癌症,包括施用本发明的化合物。
-
公开(公告)号:US20090215093A1
公开(公告)日:2009-08-27
申请号:US12434185
申请日:2009-05-01
申请人: Mark K. Bennett , Tonia J. Buchholz , Susan D. Demo , Guy J. Laidig , Evan R. Lewis , Mark S. Smyth
发明人: Mark K. Bennett , Tonia J. Buchholz , Susan D. Demo , Guy J. Laidig , Evan R. Lewis , Mark S. Smyth
IPC分类号: G01N33/566 , C12N9/99 , G01N33/53 , G01N33/573
CPC分类号: C07K5/0812 , C07K1/13 , C07K5/06165 , C07K5/0806 , C07K5/0808 , C07K5/1016 , C12Q1/34 , C12Q1/37 , G01N33/573 , G01N2333/976 , G01N2500/00
摘要: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.
摘要翻译: 包括含杂原子的三元环的基于肽的化合物有效地选择性地抑制N末端亲核试剂(Ntn)水解酶的比活性。 具有多种活性的那些Ntn的活性可被所描述的化合物差别地抑制。 例如,本发明化合物可以选择性地抑制20S蛋白酶体的胰凝乳蛋白酶样和PGPH活性。 基于肽的化合物包括至少三种肽单元,环氧化物或氮丙啶,并且在N末端官能化,例如可检测标记。 与治疗用途一起,这些基于肽的化合物可用于用于筛选,监测,诊断和/或给药目的的测定中。
-
公开(公告)号:US08697837B2
公开(公告)日:2014-04-15
申请号:US12505984
申请日:2009-07-20
IPC分类号: C07K14/00
CPC分类号: G01N33/6875 , C07K14/00 , C07K14/47 , G01N33/573
摘要: The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.
摘要翻译: 本申请提供了用作蛋白酶体酶活性的底物的肽,例如19S调节颗粒的金属蛋白酶Rpn11的酶活性。 本申请还提供了使用肽底物的方法和组合物。
-
-
-
-
-
-
-
-
-